• Press
  • Offices
  • Contact
  • Legal notice
  • EN
  • UPC
  • Firm
    • Main Focus
    • History
    • Guiding Principle
    • Awards and Rankings
  • Our Practice
    • Legal Areas
    • Industries
  • Our Team
  • Career
    • Working with us
  • News & Knowledge
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Brexit-Update
    • Publications
    • B&B Bulletin
  • Menu Menu
FIND EXPERTS
  • UPC
  • Firm
    • Main Focus
    • History
    • Guiding Principle
    • Awards and Rankings
  • News & Knowledge
    • News
    • Events
    • UPC-Update
    • IP-Update
    • Brexit-Update
    • Publications
    • B&B Bulletin
  • FIND EXPERTS
  • Contact
  • Our Practice
    • Legal Areas
    • Industries
  • Our Team
  • Career
    • Working with us
  • Offices
  • EN

European Patent Office Revokes Broad Institute’s CRISPR-Cas9 “Gene Edi­ting” Patent

1. February 2018/in Issue February 2018, Patents and Utility Models

The Opposition Division of the European Patent Office has revoked EP 2 771 468 B1, one of the fundamental CRISPR patents for lack of novelty, in essence due to formal irregularities in the priority claim. An appeal is pending.

CRISPR-Cas9 gene editing is the ground-breaking technology that has in the past 5 years tremendously transformed the field of molecular genetics, and will very likely revolutionize biomedical approaches in the future. The “CRISPR” or “gene editing” technology harnesses a bacterial defense mechanism which identifies and destroys foreign “harmful” DNA as a tool for the targeted manipulation of genomic DNA. Compared to other manipulation approaches gene editing does not leave any undesired traces or footprints in the edited genome and is easy to apply. Gene editing was developed and filed for a patent nearly at the same time by the University of California, Berkeley, and the Broad Institute of the Massachusetts Institute of Technology (MIT). Since then, both institutions bitterly fight over the control and dominance of the CRISPR patent landscape in the US and Europe.

Now, in a first instance decision, the European Patent Office (EPO) revoked Broad
Institute’s CRISPR Gene Editing Patent for a lack of novelty due to formal irregularities in the priority claim. What happened? The Broad institute originally filed a conglomerate of 12 US provisional applications in the name of the inventors disclosing their part of the CRISPR technology. These US provisional applications were then used as a basis for a priority claim in an International (PCT) application of the Broad Institute from which the later European CRISPR patent was derived (opposed European patent No. EP 2 771 468).

A valid priority claim in Europe requires that the applicant is able to demonstrate its right to priority, either through identity of applicants between the prior and subsequent applications, or by proving a transfer of the priority rights with assignment documentation. Remarkably, for the CRISPR patent, the patent owner could not provide evidence for the ownership of the priority rights for a significant number of originally filed US provisional applications. Their priority claim was rejected by the EPO resulting in a loss of the priority date and a subsequent novelty rejection. The patent was revoked during oral proceedings on January 17, 2018. However, the Broad Institute already filed a notice of appeal – so the struggle continues.

This prominent example demonstrates again the importance of a thorough and careful preparation of priority claims for Europe, in particular in cases with multiple priorities.

/wp-content/uploads/2022/04/boehmert_logo.svg 0 0 Petra Hettenkofer /wp-content/uploads/2022/04/boehmert_logo.svg Petra Hettenkofer2018-02-01 15:01:592022-08-24 12:19:01European Patent Office Revokes Broad Institute’s CRISPR-Cas9 “Gene Edi­ting” Patent

Author

Dr. David Kuttenkeuler

Contents

More articles

  • No infringement of copy­right protected product at… 1. February 2018
  • Amendments to the Ger­man Trademark Act 1. February 2018
  • Update UPC: Further De­lays and Obstacles 1. February 2018

More Articles

No infringement of copy­right protected product at (international) trade fair in Germany 01. February 2018
Amendments to the Ger­man Trademark Act 01. February 2018
Update UPC: Further De­lays and Obstacles 01. February 2018
BGH on Internet test pur­chases 01. February 2018
Implementation of the EU Trade Secret Directive – companies need to anti­cipate new developments 01. February 2018
Amendment of the tele­media act: Liability of WLAN operators will be further limited 01. February 2018
Case Law: Infringement of German Patents by Sup­plying Goods outside of Germany 01. February 2018
Countdown to GDPR – Beware of the new Data Protection Rules 01. February 2018
G 1/16 – To disclaim or not to disclaim 01. February 2018
New EPO Guidelines for Examination on the Pa­tenting of Graphical User Interfaces 01. February 2018

Menu

  • Firm
  • Our Practice
  • Career
  • News & Knowledge
  • FIND EXPERTS

Informations

  • Press
  • Contact
  • Legal notice
  • Data Protection
  • General Terms and Conditions
  • Contact

Legal Areas

  • Employee Inventions
  • Data Protection
  • Designs
  • Domains
  • Information Technology
  • Anti-Trust
  • Licencing
  • Trade Marks
  • Patent Valuation
  • Patents & Utility Models
  • Patent Litigation
  • Product Piracy
  • Copyright
  • Unfair Competition

© Copyright 2023– BOEHMERT & BOEHMERT

Scroll to top

We only use functional cookies and no third party services. Learn more in our privacy policy.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.